Published in Hepatitis Weekly, May 18th, 1998
The Taiwanese study found that 40 percent of hepatitis B virus (HBV) infected patients treated with the immune modifier became hepatitis Be antigen (HBeAg) negative and HBV DNA seronegative one year after the end of therapy ("Efficacy of Thymosin (alpha)1 in Patients with Chronic Hepatitis B: A Randomized, Controlled Trial," Hepatology, May 1998;27(5):1383-1387).
Over the past 20 years, many antiviral or immunomodulatory agents, or both, have been used in patients with chronic HBV infection. ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.